Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...

Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks. But a mistake in a larger, ...

Eli Lilly is casting a long shadow over the GLP-1 market. Structure Therapeutics linked its oral candidate to significant reductions in blood sugar and weight in a phase 2a trial on Monday, only for ...

Structure Therapeutics’ lead drug candidate is chasing big pharmaceutical rivals in the race for new oral weight-loss medications, and the company had been telling investors to expect data late this ...

Structure Therapeutics' GSBR-1290 showed a placebo-adjusted mean weight loss of 6.2% at 12 weeks, suggesting potential despite initial underwhelming results. Comparatively, Eli Lilly’s orforglipron ...